SOPHiA GENETICS S.A.
SOPHiA GENETICS S.A. (SOPH) Stock Competitors & Peer Comparison
See (SOPH) competitors and their performances in Stock Market.
Peer Comparison Table: Medical - Healthcare Information Services Industry
Detailed financial metrics including price, market cap, P/E ratio, and more.
| Symbol | Price | Change % | Market Cap | P/E Ratio | EPS | Dividend Yield |
|---|---|---|---|---|---|---|
| SOPH | $3.60 | -0.28% | 245.6M | -3.67 | -$1.00 | N/A |
| VEEV | $290.41 | -0.29% | 47.5B | 61.55 | $4.72 | N/A |
| GEHC | $77.61 | +1.09% | 35.5B | 16.30 | $4.76 | +0.17% |
| GEHCV | $56.00 | -4.08% | 25.5B | N/A | N/A | +0.17% |
| DOCS | $60.77 | +0.20% | 11.4B | 54.74 | $1.11 | N/A |
| SGFY | $30.49 | +0.07% | 8.9B | 70.91 | $0.43 | N/A |
| HQY | $96.04 | +1.76% | 8.3B | 70.10 | $1.37 | N/A |
| RCM | $14.31 | N/A | 6B | -102.21 | -$0.14 | N/A |
| BTSGU | $72.59 | -1.16% | 3.7B | N/A | N/A | N/A |
| BTSG | $20.53 | -0.63% | 3.6B | 76.04 | $0.27 | N/A |
Stock Comparison
SOPH vs VEEV Comparison July 2025
SOPH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SOPH stands at 245.6M. In comparison, VEEV has a market cap of 47.5B. Regarding current trading prices, SOPH is priced at $3.60, while VEEV trades at $290.41.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SOPH currently has a P/E ratio of -3.67, whereas VEEV's P/E ratio is 61.55. In terms of profitability, SOPH's ROE is -0.63%, compared to VEEV's ROE of +0.14%. Regarding short-term risk, SOPH is more volatile compared to VEEV. This indicates potentially higher risk in terms of short-term price fluctuations for SOPH.Check VEEV's competition here
SOPH vs GEHC Comparison July 2025
SOPH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SOPH stands at 245.6M. In comparison, GEHC has a market cap of 35.5B. Regarding current trading prices, SOPH is priced at $3.60, while GEHC trades at $77.61.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SOPH currently has a P/E ratio of -3.67, whereas GEHC's P/E ratio is 16.30. In terms of profitability, SOPH's ROE is -0.63%, compared to GEHC's ROE of +0.26%. Regarding short-term risk, SOPH is more volatile compared to GEHC. This indicates potentially higher risk in terms of short-term price fluctuations for SOPH.Check GEHC's competition here
SOPH vs GEHCV Comparison July 2025
SOPH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SOPH stands at 245.6M. In comparison, GEHCV has a market cap of 25.5B. Regarding current trading prices, SOPH is priced at $3.60, while GEHCV trades at $56.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SOPH currently has a P/E ratio of -3.67, whereas GEHCV's P/E ratio is N/A. In terms of profitability, SOPH's ROE is -0.63%, compared to GEHCV's ROE of +0.26%. Regarding short-term risk, SOPH is less volatile compared to GEHCV. This indicates potentially lower risk in terms of short-term price fluctuations for SOPH.Check GEHCV's competition here
SOPH vs DOCS Comparison July 2025
SOPH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SOPH stands at 245.6M. In comparison, DOCS has a market cap of 11.4B. Regarding current trading prices, SOPH is priced at $3.60, while DOCS trades at $60.77.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SOPH currently has a P/E ratio of -3.67, whereas DOCS's P/E ratio is 54.74. In terms of profitability, SOPH's ROE is -0.63%, compared to DOCS's ROE of +0.22%. Regarding short-term risk, SOPH is more volatile compared to DOCS. This indicates potentially higher risk in terms of short-term price fluctuations for SOPH.Check DOCS's competition here
SOPH vs SGFY Comparison July 2025
SOPH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SOPH stands at 245.6M. In comparison, SGFY has a market cap of 8.9B. Regarding current trading prices, SOPH is priced at $3.60, while SGFY trades at $30.49.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SOPH currently has a P/E ratio of -3.67, whereas SGFY's P/E ratio is 70.91. In terms of profitability, SOPH's ROE is -0.63%, compared to SGFY's ROE of -0.15%. Regarding short-term risk, SOPH is more volatile compared to SGFY. This indicates potentially higher risk in terms of short-term price fluctuations for SOPH.Check SGFY's competition here
SOPH vs HQY Comparison July 2025
SOPH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SOPH stands at 245.6M. In comparison, HQY has a market cap of 8.3B. Regarding current trading prices, SOPH is priced at $3.60, while HQY trades at $96.04.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SOPH currently has a P/E ratio of -3.67, whereas HQY's P/E ratio is 70.10. In terms of profitability, SOPH's ROE is -0.63%, compared to HQY's ROE of +0.06%. Regarding short-term risk, SOPH is more volatile compared to HQY. This indicates potentially higher risk in terms of short-term price fluctuations for SOPH.Check HQY's competition here
SOPH vs RCM Comparison July 2025
SOPH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SOPH stands at 245.6M. In comparison, RCM has a market cap of 6B. Regarding current trading prices, SOPH is priced at $3.60, while RCM trades at $14.31.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SOPH currently has a P/E ratio of -3.67, whereas RCM's P/E ratio is -102.21. In terms of profitability, SOPH's ROE is -0.63%, compared to RCM's ROE of -0.02%. Regarding short-term risk, SOPH is more volatile compared to RCM. This indicates potentially higher risk in terms of short-term price fluctuations for SOPH.Check RCM's competition here
SOPH vs BTSGU Comparison July 2025
SOPH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SOPH stands at 245.6M. In comparison, BTSGU has a market cap of 3.7B. Regarding current trading prices, SOPH is priced at $3.60, while BTSGU trades at $72.59.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SOPH currently has a P/E ratio of -3.67, whereas BTSGU's P/E ratio is N/A. In terms of profitability, SOPH's ROE is -0.63%, compared to BTSGU's ROE of +0.03%. Regarding short-term risk, SOPH is more volatile compared to BTSGU. This indicates potentially higher risk in terms of short-term price fluctuations for SOPH.Check BTSGU's competition here
SOPH vs BTSG Comparison July 2025
SOPH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SOPH stands at 245.6M. In comparison, BTSG has a market cap of 3.6B. Regarding current trading prices, SOPH is priced at $3.60, while BTSG trades at $20.53.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SOPH currently has a P/E ratio of -3.67, whereas BTSG's P/E ratio is 76.04. In terms of profitability, SOPH's ROE is -0.63%, compared to BTSG's ROE of +0.03%. Regarding short-term risk, SOPH is more volatile compared to BTSG. This indicates potentially higher risk in terms of short-term price fluctuations for SOPH.Check BTSG's competition here
SOPH vs ONEM Comparison July 2025
SOPH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SOPH stands at 245.6M. In comparison, ONEM has a market cap of 3.4B. Regarding current trading prices, SOPH is priced at $3.60, while ONEM trades at $16.47.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SOPH currently has a P/E ratio of -3.67, whereas ONEM's P/E ratio is -7.77. In terms of profitability, SOPH's ROE is -0.63%, compared to ONEM's ROE of -0.24%. Regarding short-term risk, SOPH is less volatile compared to ONEM. This indicates potentially lower risk in terms of short-term price fluctuations for SOPH.Check ONEM's competition here
SOPH vs PRVA Comparison July 2025
SOPH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SOPH stands at 245.6M. In comparison, PRVA has a market cap of 2.4B. Regarding current trading prices, SOPH is priced at $3.60, while PRVA trades at $19.71.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SOPH currently has a P/E ratio of -3.67, whereas PRVA's P/E ratio is 164.21. In terms of profitability, SOPH's ROE is -0.63%, compared to PRVA's ROE of +0.02%. Regarding short-term risk, SOPH is more volatile compared to PRVA. This indicates potentially higher risk in terms of short-term price fluctuations for SOPH.Check PRVA's competition here
SOPH vs WGS Comparison July 2025
SOPH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SOPH stands at 245.6M. In comparison, WGS has a market cap of 2.3B. Regarding current trading prices, SOPH is priced at $3.60, while WGS trades at $79.83.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SOPH currently has a P/E ratio of -3.67, whereas WGS's P/E ratio is -57.43. In terms of profitability, SOPH's ROE is -0.63%, compared to WGS's ROE of -0.17%. Regarding short-term risk, SOPH is less volatile compared to WGS. This indicates potentially lower risk in terms of short-term price fluctuations for SOPH.Check WGS's competition here
SOPH vs PGNY Comparison July 2025
SOPH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SOPH stands at 245.6M. In comparison, PGNY has a market cap of 2B. Regarding current trading prices, SOPH is priced at $3.60, while PGNY trades at $23.11.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SOPH currently has a P/E ratio of -3.67, whereas PGNY's P/E ratio is 40.54. In terms of profitability, SOPH's ROE is -0.63%, compared to PGNY's ROE of +0.12%. Regarding short-term risk, SOPH is more volatile compared to PGNY. This indicates potentially higher risk in terms of short-term price fluctuations for SOPH.Check PGNY's competition here
SOPH vs CERT Comparison July 2025
SOPH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SOPH stands at 245.6M. In comparison, CERT has a market cap of 1.8B. Regarding current trading prices, SOPH is priced at $3.60, while CERT trades at $11.09.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SOPH currently has a P/E ratio of -3.67, whereas CERT's P/E ratio is -555.00. In terms of profitability, SOPH's ROE is -0.63%, compared to CERT's ROE of -0.00%. Regarding short-term risk, SOPH is more volatile compared to CERT. This indicates potentially higher risk in terms of short-term price fluctuations for SOPH.Check CERT's competition here
SOPH vs GDRX Comparison July 2025
SOPH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SOPH stands at 245.6M. In comparison, GDRX has a market cap of 1.8B. Regarding current trading prices, SOPH is priced at $3.60, while GDRX trades at $5.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SOPH currently has a P/E ratio of -3.67, whereas GDRX's P/E ratio is 71.43. In terms of profitability, SOPH's ROE is -0.63%, compared to GDRX's ROE of +0.07%. Regarding short-term risk, SOPH is more volatile compared to GDRX. This indicates potentially higher risk in terms of short-term price fluctuations for SOPH.Check GDRX's competition here
SOPH vs TXG Comparison July 2025
SOPH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SOPH stands at 245.6M. In comparison, TXG has a market cap of 1.8B. Regarding current trading prices, SOPH is priced at $3.60, while TXG trades at $14.11.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SOPH currently has a P/E ratio of -3.67, whereas TXG's P/E ratio is -10.85. In terms of profitability, SOPH's ROE is -0.63%, compared to TXG's ROE of -0.22%. Regarding short-term risk, SOPH is less volatile compared to TXG. This indicates potentially lower risk in terms of short-term price fluctuations for SOPH.Check TXG's competition here
SOPH vs PINC Comparison July 2025
SOPH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SOPH stands at 245.6M. In comparison, PINC has a market cap of 1.7B. Regarding current trading prices, SOPH is priced at $3.60, while PINC trades at $21.18.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SOPH currently has a P/E ratio of -3.67, whereas PINC's P/E ratio is 20.76. In terms of profitability, SOPH's ROE is -0.63%, compared to PINC's ROE of +0.03%. Regarding short-term risk, SOPH is more volatile compared to PINC. This indicates potentially higher risk in terms of short-term price fluctuations for SOPH.Check PINC's competition here
SOPH vs SDGR Comparison July 2025
SOPH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SOPH stands at 245.6M. In comparison, SDGR has a market cap of 1.6B. Regarding current trading prices, SOPH is priced at $3.60, while SDGR trades at $22.23.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SOPH currently has a P/E ratio of -3.67, whereas SDGR's P/E ratio is -8.45. In terms of profitability, SOPH's ROE is -0.63%, compared to SDGR's ROE of -0.45%. Regarding short-term risk, SOPH is more volatile compared to SDGR. This indicates potentially higher risk in terms of short-term price fluctuations for SOPH.Check SDGR's competition here
SOPH vs NXGN Comparison July 2025
SOPH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SOPH stands at 245.6M. In comparison, NXGN has a market cap of 1.6B. Regarding current trading prices, SOPH is priced at $3.60, while NXGN trades at $23.94.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SOPH currently has a P/E ratio of -3.67, whereas NXGN's P/E ratio is -266.00. In terms of profitability, SOPH's ROE is -0.63%, compared to NXGN's ROE of -0.01%. Regarding short-term risk, SOPH is more volatile compared to NXGN. This indicates potentially higher risk in terms of short-term price fluctuations for SOPH.Check NXGN's competition here
SOPH vs PHR Comparison July 2025
SOPH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SOPH stands at 245.6M. In comparison, PHR has a market cap of 1.6B. Regarding current trading prices, SOPH is priced at $3.60, while PHR trades at $26.63.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SOPH currently has a P/E ratio of -3.67, whereas PHR's P/E ratio is -36.00. In terms of profitability, SOPH's ROE is -0.63%, compared to PHR's ROE of -0.16%. Regarding short-term risk, SOPH is more volatile compared to PHR. This indicates potentially higher risk in terms of short-term price fluctuations for SOPH.Check PHR's competition here
SOPH vs TDOC Comparison July 2025
SOPH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SOPH stands at 245.6M. In comparison, TDOC has a market cap of 1.4B. Regarding current trading prices, SOPH is priced at $3.60, while TDOC trades at $8.20.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SOPH currently has a P/E ratio of -3.67, whereas TDOC's P/E ratio is -1.39. In terms of profitability, SOPH's ROE is -0.63%, compared to TDOC's ROE of -0.68%. Regarding short-term risk, SOPH is less volatile compared to TDOC. This indicates potentially lower risk in terms of short-term price fluctuations for SOPH.Check TDOC's competition here
SOPH vs AGTI Comparison July 2025
SOPH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SOPH stands at 245.6M. In comparison, AGTI has a market cap of 1.4B. Regarding current trading prices, SOPH is priced at $3.60, while AGTI trades at $10.05.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SOPH currently has a P/E ratio of -3.67, whereas AGTI's P/E ratio is -71.79. In terms of profitability, SOPH's ROE is -0.63%, compared to AGTI's ROE of -0.01%. Regarding short-term risk, SOPH is more volatile compared to AGTI. This indicates potentially higher risk in terms of short-term price fluctuations for SOPH.Check AGTI's competition here
SOPH vs OMCL Comparison July 2025
SOPH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SOPH stands at 245.6M. In comparison, OMCL has a market cap of 1.3B. Regarding current trading prices, SOPH is priced at $3.60, while OMCL trades at $28.27.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SOPH currently has a P/E ratio of -3.67, whereas OMCL's P/E ratio is 61.46. In terms of profitability, SOPH's ROE is -0.63%, compared to OMCL's ROE of +0.02%. Regarding short-term risk, SOPH is more volatile compared to OMCL. This indicates potentially higher risk in terms of short-term price fluctuations for SOPH.Check OMCL's competition here
SOPH vs EVH Comparison July 2025
SOPH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SOPH stands at 245.6M. In comparison, EVH has a market cap of 1.2B. Regarding current trading prices, SOPH is priced at $3.60, while EVH trades at $9.93.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SOPH currently has a P/E ratio of -3.67, whereas EVH's P/E ratio is -8.14. In terms of profitability, SOPH's ROE is -0.63%, compared to EVH's ROE of -0.11%. Regarding short-term risk, SOPH is less volatile compared to EVH. This indicates potentially lower risk in terms of short-term price fluctuations for SOPH.Check EVH's competition here
SOPH vs HSTM Comparison July 2025
SOPH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SOPH stands at 245.6M. In comparison, HSTM has a market cap of 816.6M. Regarding current trading prices, SOPH is priced at $3.60, while HSTM trades at $26.75.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SOPH currently has a P/E ratio of -3.67, whereas HSTM's P/E ratio is 42.46. In terms of profitability, SOPH's ROE is -0.63%, compared to HSTM's ROE of +0.05%. Regarding short-term risk, SOPH is more volatile compared to HSTM. This indicates potentially higher risk in terms of short-term price fluctuations for SOPH.Check HSTM's competition here
SOPH vs CTEV Comparison July 2025
SOPH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SOPH stands at 245.6M. In comparison, CTEV has a market cap of 651.8M. Regarding current trading prices, SOPH is priced at $3.60, while CTEV trades at $39.68.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SOPH currently has a P/E ratio of -3.67, whereas CTEV's P/E ratio is -0.54. In terms of profitability, SOPH's ROE is -0.63%, compared to CTEV's ROE of -5.18%. Regarding short-term risk, SOPH is less volatile compared to CTEV. This indicates potentially lower risk in terms of short-term price fluctuations for SOPH.Check CTEV's competition here
SOPH vs MPLN-WT Comparison July 2025
SOPH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SOPH stands at 245.6M. In comparison, MPLN-WT has a market cap of 625.2M. Regarding current trading prices, SOPH is priced at $3.60, while MPLN-WT trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SOPH currently has a P/E ratio of -3.67, whereas MPLN-WT's P/E ratio is N/A. In terms of profitability, SOPH's ROE is -0.63%, compared to MPLN-WT's ROE of -5.18%. Regarding short-term risk, SOPH is less volatile compared to MPLN-WT. This indicates potentially lower risk in terms of short-term price fluctuations for SOPH.Check MPLN-WT's competition here
SOPH vs SY Comparison July 2025
SOPH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SOPH stands at 245.6M. In comparison, SY has a market cap of 604.5M. Regarding current trading prices, SOPH is priced at $3.60, while SY trades at $4.64.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SOPH currently has a P/E ratio of -3.67, whereas SY's P/E ratio is -5.73. In terms of profitability, SOPH's ROE is -0.63%, compared to SY's ROE of -0.28%. Regarding short-term risk, SOPH is less volatile compared to SY. This indicates potentially lower risk in terms of short-term price fluctuations for SOPH.Check SY's competition here
SOPH vs ACCD Comparison July 2025
SOPH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SOPH stands at 245.6M. In comparison, ACCD has a market cap of 575.6M. Regarding current trading prices, SOPH is priced at $3.60, while ACCD trades at $7.02.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SOPH currently has a P/E ratio of -3.67, whereas ACCD's P/E ratio is -3.08. In terms of profitability, SOPH's ROE is -0.63%, compared to ACCD's ROE of -0.45%. Regarding short-term risk, SOPH is more volatile compared to ACCD. This indicates potentially higher risk in terms of short-term price fluctuations for SOPH.Check ACCD's competition here
SOPH vs SHCR Comparison July 2025
SOPH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SOPH stands at 245.6M. In comparison, SHCR has a market cap of 531.8M. Regarding current trading prices, SOPH is priced at $3.60, while SHCR trades at $1.43.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SOPH currently has a P/E ratio of -3.67, whereas SHCR's P/E ratio is -3.76. In terms of profitability, SOPH's ROE is -0.63%, compared to SHCR's ROE of -0.24%. Regarding short-term risk, SOPH is more volatile compared to SHCR. This indicates potentially higher risk in terms of short-term price fluctuations for SOPH.Check SHCR's competition here
SOPH vs NUTX Comparison July 2025
SOPH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SOPH stands at 245.6M. In comparison, NUTX has a market cap of 526.7M. Regarding current trading prices, SOPH is priced at $3.60, while NUTX trades at $95.02.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SOPH currently has a P/E ratio of -3.67, whereas NUTX's P/E ratio is 7.68. In terms of profitability, SOPH's ROE is -0.63%, compared to NUTX's ROE of +0.71%. Regarding short-term risk, SOPH is less volatile compared to NUTX. This indicates potentially lower risk in terms of short-term price fluctuations for SOPH.Check NUTX's competition here
SOPH vs DH Comparison July 2025
SOPH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SOPH stands at 245.6M. In comparison, DH has a market cap of 439.6M. Regarding current trading prices, SOPH is priced at $3.60, while DH trades at $4.10.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SOPH currently has a P/E ratio of -3.67, whereas DH's P/E ratio is -0.93. In terms of profitability, SOPH's ROE is -0.63%, compared to DH's ROE of -1.07%. Regarding short-term risk, SOPH is less volatile compared to DH. This indicates potentially lower risk in terms of short-term price fluctuations for SOPH.Check DH's competition here
SOPH vs SLGC Comparison July 2025
SOPH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SOPH stands at 245.6M. In comparison, SLGC has a market cap of 396.2M. Regarding current trading prices, SOPH is priced at $3.60, while SLGC trades at $2.10.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SOPH currently has a P/E ratio of -3.67, whereas SLGC's P/E ratio is -3.04. In terms of profitability, SOPH's ROE is -0.63%, compared to SLGC's ROE of -0.19%. Regarding short-term risk, SOPH is less volatile compared to SLGC. This indicates potentially lower risk in terms of short-term price fluctuations for SOPH.Check SLGC's competition here
SOPH vs SLGCW Comparison July 2025
SOPH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SOPH stands at 245.6M. In comparison, SLGCW has a market cap of 396.2M. Regarding current trading prices, SOPH is priced at $3.60, while SLGCW trades at $0.09.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SOPH currently has a P/E ratio of -3.67, whereas SLGCW's P/E ratio is -0.16. In terms of profitability, SOPH's ROE is -0.63%, compared to SLGCW's ROE of -0.19%. Regarding short-term risk, SOPH is less volatile compared to SLGCW. This indicates potentially lower risk in terms of short-term price fluctuations for SOPH.Check SLGCW's competition here
SOPH vs MPLN Comparison July 2025
SOPH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SOPH stands at 245.6M. In comparison, MPLN has a market cap of 375M. Regarding current trading prices, SOPH is priced at $3.60, while MPLN trades at $23.15.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SOPH currently has a P/E ratio of -3.67, whereas MPLN's P/E ratio is -0.23. In terms of profitability, SOPH's ROE is -0.63%, compared to MPLN's ROE of -5.18%. Regarding short-term risk, SOPH is less volatile compared to MPLN. This indicates potentially lower risk in terms of short-term price fluctuations for SOPH.Check MPLN's competition here
SOPH vs SPOK Comparison July 2025
SOPH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SOPH stands at 245.6M. In comparison, SPOK has a market cap of 359.4M. Regarding current trading prices, SOPH is priced at $3.60, while SPOK trades at $17.47.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SOPH currently has a P/E ratio of -3.67, whereas SPOK's P/E ratio is 22.69. In terms of profitability, SOPH's ROE is -0.63%, compared to SPOK's ROE of +0.10%. Regarding short-term risk, SOPH is more volatile compared to SPOK. This indicates potentially higher risk in terms of short-term price fluctuations for SOPH.Check SPOK's competition here
SOPH vs TBRG Comparison July 2025
SOPH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SOPH stands at 245.6M. In comparison, TBRG has a market cap of 353M. Regarding current trading prices, SOPH is priced at $3.60, while TBRG trades at $23.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SOPH currently has a P/E ratio of -3.67, whereas TBRG's P/E ratio is -19.26. In terms of profitability, SOPH's ROE is -0.63%, compared to TBRG's ROE of -0.10%. Regarding short-term risk, SOPH is more volatile compared to TBRG. This indicates potentially higher risk in terms of short-term price fluctuations for SOPH.Check TBRG's competition here
SOPH vs NRC Comparison July 2025
SOPH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SOPH stands at 245.6M. In comparison, NRC has a market cap of 316.5M. Regarding current trading prices, SOPH is priced at $3.60, while NRC trades at $13.89.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SOPH currently has a P/E ratio of -3.67, whereas NRC's P/E ratio is 13.62. In terms of profitability, SOPH's ROE is -0.63%, compared to NRC's ROE of +0.71%. Regarding short-term risk, SOPH is less volatile compared to NRC. This indicates potentially lower risk in terms of short-term price fluctuations for SOPH.Check NRC's competition here
SOPH vs TRHC Comparison July 2025
SOPH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SOPH stands at 245.6M. In comparison, TRHC has a market cap of 284M. Regarding current trading prices, SOPH is priced at $3.60, while TRHC trades at $10.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SOPH currently has a P/E ratio of -3.67, whereas TRHC's P/E ratio is -4.27. In terms of profitability, SOPH's ROE is -0.63%, compared to TRHC's ROE of +121.31%. Regarding short-term risk, SOPH is more volatile compared to TRHC. This indicates potentially higher risk in terms of short-term price fluctuations for SOPH.Check TRHC's competition here
SOPH vs HCAT Comparison July 2025
SOPH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SOPH stands at 245.6M. In comparison, HCAT has a market cap of 270.1M. Regarding current trading prices, SOPH is priced at $3.60, while HCAT trades at $3.88.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SOPH currently has a P/E ratio of -3.67, whereas HCAT's P/E ratio is -3.37. In terms of profitability, SOPH's ROE is -0.63%, compared to HCAT's ROE of -0.20%. Regarding short-term risk, SOPH is less volatile compared to HCAT. This indicates potentially lower risk in terms of short-term price fluctuations for SOPH.Check HCAT's competition here
SOPH vs SLP Comparison July 2025
SOPH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SOPH stands at 245.6M. In comparison, SLP has a market cap of 266.3M. Regarding current trading prices, SOPH is priced at $3.60, while SLP trades at $13.23.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SOPH currently has a P/E ratio of -3.67, whereas SLP's P/E ratio is -4.20. In terms of profitability, SOPH's ROE is -0.63%, compared to SLP's ROE of -0.37%. Regarding short-term risk, SOPH is more volatile compared to SLP. This indicates potentially higher risk in terms of short-term price fluctuations for SOPH.Check SLP's competition here
SOPH vs OPRX Comparison July 2025
SOPH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SOPH stands at 245.6M. In comparison, OPRX has a market cap of 265.4M. Regarding current trading prices, SOPH is priced at $3.60, while OPRX trades at $14.35.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SOPH currently has a P/E ratio of -3.67, whereas OPRX's P/E ratio is -17.08. In terms of profitability, SOPH's ROE is -0.63%, compared to OPRX's ROE of -0.13%. Regarding short-term risk, SOPH is less volatile compared to OPRX. This indicates potentially lower risk in terms of short-term price fluctuations for SOPH.Check OPRX's competition here
SOPH vs SMFR Comparison July 2025
SOPH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SOPH stands at 245.6M. In comparison, SMFR has a market cap of 246.4M. Regarding current trading prices, SOPH is priced at $3.60, while SMFR trades at $0.31.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SOPH currently has a P/E ratio of -3.67, whereas SMFR's P/E ratio is N/A. In terms of profitability, SOPH's ROE is -0.63%, compared to SMFR's ROE of -0.17%. Regarding short-term risk, SOPH is less volatile compared to SMFR. This indicates potentially lower risk in terms of short-term price fluctuations for SOPH.Check SMFR's competition here
SOPH vs AMWL Comparison July 2025
SOPH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SOPH stands at 245.6M. In comparison, AMWL has a market cap of 142M. Regarding current trading prices, SOPH is priced at $3.60, while AMWL trades at $8.96.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SOPH currently has a P/E ratio of -3.67, whereas AMWL's P/E ratio is -0.89. In terms of profitability, SOPH's ROE is -0.63%, compared to AMWL's ROE of -0.48%. Regarding short-term risk, SOPH is less volatile compared to AMWL. This indicates potentially lower risk in terms of short-term price fluctuations for SOPH.Check AMWL's competition here
SOPH vs CPSI Comparison July 2025
SOPH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SOPH stands at 245.6M. In comparison, CPSI has a market cap of 133.7M. Regarding current trading prices, SOPH is priced at $3.60, while CPSI trades at $9.19.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SOPH currently has a P/E ratio of -3.67, whereas CPSI's P/E ratio is -183.80. In terms of profitability, SOPH's ROE is -0.63%, compared to CPSI's ROE of -0.18%. Regarding short-term risk, SOPH is less volatile compared to CPSI. This indicates potentially lower risk in terms of short-term price fluctuations for SOPH.Check CPSI's competition here
SOPH vs EUDA Comparison July 2025
SOPH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SOPH stands at 245.6M. In comparison, EUDA has a market cap of 118.9M. Regarding current trading prices, SOPH is priced at $3.60, while EUDA trades at $3.18.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SOPH currently has a P/E ratio of -3.67, whereas EUDA's P/E ratio is -5.93. In terms of profitability, SOPH's ROE is -0.63%, compared to EUDA's ROE of +3.05%. Regarding short-term risk, SOPH is less volatile compared to EUDA. This indicates potentially lower risk in terms of short-term price fluctuations for SOPH.Check EUDA's competition here
SOPH vs AUGX Comparison July 2025
SOPH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SOPH stands at 245.6M. In comparison, AUGX has a market cap of 115.9M. Regarding current trading prices, SOPH is priced at $3.60, while AUGX trades at $2.35.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SOPH currently has a P/E ratio of -3.67, whereas AUGX's P/E ratio is -4.99. In terms of profitability, SOPH's ROE is -0.63%, compared to AUGX's ROE of -1.13%. Regarding short-term risk, SOPH is more volatile compared to AUGX. This indicates potentially higher risk in terms of short-term price fluctuations for SOPH.Check AUGX's competition here
SOPH vs CCLDO Comparison July 2025
SOPH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SOPH stands at 245.6M. In comparison, CCLDO has a market cap of 104.2M. Regarding current trading prices, SOPH is priced at $3.60, while CCLDO trades at $19.90.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SOPH currently has a P/E ratio of -3.67, whereas CCLDO's P/E ratio is N/A. In terms of profitability, SOPH's ROE is -0.63%, compared to CCLDO's ROE of +0.21%. Regarding short-term risk, SOPH is more volatile compared to CCLDO. This indicates potentially higher risk in terms of short-term price fluctuations for SOPH.Check CCLDO's competition here
SOPH vs CCLD Comparison July 2025
SOPH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SOPH stands at 245.6M. In comparison, CCLD has a market cap of 103.7M. Regarding current trading prices, SOPH is priced at $3.60, while CCLD trades at $2.45.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SOPH currently has a P/E ratio of -3.67, whereas CCLD's P/E ratio is -11.14. In terms of profitability, SOPH's ROE is -0.63%, compared to CCLD's ROE of +0.21%. Regarding short-term risk, SOPH is less volatile compared to CCLD. This indicates potentially lower risk in terms of short-term price fluctuations for SOPH.Check CCLD's competition here
SOPH vs FORA Comparison July 2025
SOPH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SOPH stands at 245.6M. In comparison, FORA has a market cap of 60.2M. Regarding current trading prices, SOPH is priced at $3.60, while FORA trades at $1.94.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SOPH currently has a P/E ratio of -3.67, whereas FORA's P/E ratio is -16.08. In terms of profitability, SOPH's ROE is -0.63%, compared to FORA's ROE of -0.13%. Regarding short-term risk, SOPH is more volatile compared to FORA. This indicates potentially higher risk in terms of short-term price fluctuations for SOPH.Check FORA's competition here
SOPH vs CCLDP Comparison July 2025
SOPH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SOPH stands at 245.6M. In comparison, CCLDP has a market cap of 59.9M. Regarding current trading prices, SOPH is priced at $3.60, while CCLDP trades at $19.43.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SOPH currently has a P/E ratio of -3.67, whereas CCLDP's P/E ratio is N/A. In terms of profitability, SOPH's ROE is -0.63%, compared to CCLDP's ROE of +0.21%. Regarding short-term risk, SOPH is more volatile compared to CCLDP. This indicates potentially higher risk in terms of short-term price fluctuations for SOPH.Check CCLDP's competition here
SOPH vs BEATW Comparison July 2025
SOPH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SOPH stands at 245.6M. In comparison, BEATW has a market cap of 51.1M. Regarding current trading prices, SOPH is priced at $3.60, while BEATW trades at $0.30.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SOPH currently has a P/E ratio of -3.67, whereas BEATW's P/E ratio is -0.60. In terms of profitability, SOPH's ROE is -0.63%, compared to BEATW's ROE of -3.58%. Regarding short-term risk, SOPH is less volatile compared to BEATW. This indicates potentially lower risk in terms of short-term price fluctuations for SOPH.Check BEATW's competition here
SOPH vs BEAT Comparison July 2025
SOPH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SOPH stands at 245.6M. In comparison, BEAT has a market cap of 42.9M. Regarding current trading prices, SOPH is priced at $3.60, while BEAT trades at $1.27.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SOPH currently has a P/E ratio of -3.67, whereas BEAT's P/E ratio is -1.72. In terms of profitability, SOPH's ROE is -0.63%, compared to BEAT's ROE of -3.58%. Regarding short-term risk, SOPH is more volatile compared to BEAT. This indicates potentially higher risk in terms of short-term price fluctuations for SOPH.Check BEAT's competition here
SOPH vs SNCE Comparison July 2025
SOPH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SOPH stands at 245.6M. In comparison, SNCE has a market cap of 34.7M. Regarding current trading prices, SOPH is priced at $3.60, while SNCE trades at $5.75.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SOPH currently has a P/E ratio of -3.67, whereas SNCE's P/E ratio is -0.27. In terms of profitability, SOPH's ROE is -0.63%, compared to SNCE's ROE of -0.47%. Regarding short-term risk, SOPH is more volatile compared to SNCE. This indicates potentially higher risk in terms of short-term price fluctuations for SOPH.Check SNCE's competition here
SOPH vs AKLI Comparison July 2025
SOPH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SOPH stands at 245.6M. In comparison, AKLI has a market cap of 34.1M. Regarding current trading prices, SOPH is priced at $3.60, while AKLI trades at $0.43.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SOPH currently has a P/E ratio of -3.67, whereas AKLI's P/E ratio is -0.71. In terms of profitability, SOPH's ROE is -0.63%, compared to AKLI's ROE of -0.38%. Regarding short-term risk, SOPH is more volatile compared to AKLI. This indicates potentially higher risk in terms of short-term price fluctuations for SOPH.Check AKLI's competition here
SOPH vs SHLT Comparison July 2025
SOPH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SOPH stands at 245.6M. In comparison, SHLT has a market cap of 33.6M. Regarding current trading prices, SOPH is priced at $3.60, while SHLT trades at $2.05.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SOPH currently has a P/E ratio of -3.67, whereas SHLT's P/E ratio is -3.87. In terms of profitability, SOPH's ROE is -0.63%, compared to SHLT's ROE of -0.07%. Regarding short-term risk, SOPH is more volatile compared to SHLT. This indicates potentially higher risk in terms of short-term price fluctuations for SOPH.Check SHLT's competition here
SOPH vs SHCRW Comparison July 2025
SOPH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SOPH stands at 245.6M. In comparison, SHCRW has a market cap of 32.5M. Regarding current trading prices, SOPH is priced at $3.60, while SHCRW trades at $0.09.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SOPH currently has a P/E ratio of -3.67, whereas SHCRW's P/E ratio is -0.00. In terms of profitability, SOPH's ROE is -0.63%, compared to SHCRW's ROE of -0.24%. Regarding short-term risk, SOPH is less volatile compared to SHCRW. This indicates potentially lower risk in terms of short-term price fluctuations for SOPH.Check SHCRW's competition here
SOPH vs HCTI Comparison July 2025
SOPH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SOPH stands at 245.6M. In comparison, HCTI has a market cap of 28M. Regarding current trading prices, SOPH is priced at $3.60, while HCTI trades at $0.07.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SOPH currently has a P/E ratio of -3.67, whereas HCTI's P/E ratio is -0.08. In terms of profitability, SOPH's ROE is -0.63%, compared to HCTI's ROE of -23.25%. Regarding short-term risk, SOPH is less volatile compared to HCTI. This indicates potentially lower risk in terms of short-term price fluctuations for SOPH.Check HCTI's competition here
SOPH vs SCNX Comparison July 2025
SOPH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SOPH stands at 245.6M. In comparison, SCNX has a market cap of 26.1M. Regarding current trading prices, SOPH is priced at $3.60, while SCNX trades at $1.99.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SOPH currently has a P/E ratio of -3.67, whereas SCNX's P/E ratio is 3.02. In terms of profitability, SOPH's ROE is -0.63%, compared to SCNX's ROE of -0.24%. Regarding short-term risk, SOPH is less volatile compared to SCNX. This indicates potentially lower risk in terms of short-term price fluctuations for SOPH.Check SCNX's competition here
SOPH vs STRM Comparison July 2025
SOPH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SOPH stands at 245.6M. In comparison, STRM has a market cap of 23.1M. Regarding current trading prices, SOPH is priced at $3.60, while STRM trades at $5.31.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SOPH currently has a P/E ratio of -3.67, whereas STRM's P/E ratio is -2.39. In terms of profitability, SOPH's ROE is -0.63%, compared to STRM's ROE of -0.68%. Regarding short-term risk, SOPH is more volatile compared to STRM. This indicates potentially higher risk in terms of short-term price fluctuations for SOPH.Check STRM's competition here
SOPH vs VSEEW Comparison July 2025
SOPH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SOPH stands at 245.6M. In comparison, VSEEW has a market cap of 23M. Regarding current trading prices, SOPH is priced at $3.60, while VSEEW trades at $0.06.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SOPH currently has a P/E ratio of -3.67, whereas VSEEW's P/E ratio is N/A. In terms of profitability, SOPH's ROE is -0.63%, compared to VSEEW's ROE of -6.10%. Regarding short-term risk, SOPH is less volatile compared to VSEEW. This indicates potentially lower risk in terms of short-term price fluctuations for SOPH.Check VSEEW's competition here
SOPH vs RNLX Comparison July 2025
SOPH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SOPH stands at 245.6M. In comparison, RNLX has a market cap of 22.5M. Regarding current trading prices, SOPH is priced at $3.60, while RNLX trades at $0.21.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SOPH currently has a P/E ratio of -3.67, whereas RNLX's P/E ratio is -0.33. In terms of profitability, SOPH's ROE is -0.63%, compared to RNLX's ROE of +1.94%. Regarding short-term risk, SOPH is less volatile compared to RNLX. This indicates potentially lower risk in terms of short-term price fluctuations for SOPH.Check RNLX's competition here
SOPH vs LIFW Comparison July 2025
SOPH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SOPH stands at 245.6M. In comparison, LIFW has a market cap of 22.4M. Regarding current trading prices, SOPH is priced at $3.60, while LIFW trades at $3.24.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SOPH currently has a P/E ratio of -3.67, whereas LIFW's P/E ratio is -0.02. In terms of profitability, SOPH's ROE is -0.63%, compared to LIFW's ROE of -3.08%. Regarding short-term risk, SOPH is more volatile compared to LIFW. This indicates potentially higher risk in terms of short-term price fluctuations for SOPH.Check LIFW's competition here
SOPH vs VSEE Comparison July 2025
SOPH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SOPH stands at 245.6M. In comparison, VSEE has a market cap of 20.8M. Regarding current trading prices, SOPH is priced at $3.60, while VSEE trades at $1.33.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SOPH currently has a P/E ratio of -3.67, whereas VSEE's P/E ratio is -13.30. In terms of profitability, SOPH's ROE is -0.63%, compared to VSEE's ROE of -6.10%. Regarding short-term risk, SOPH is less volatile compared to VSEE. This indicates potentially lower risk in terms of short-term price fluctuations for SOPH.Check VSEE's competition here
SOPH vs MGRX Comparison July 2025
SOPH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SOPH stands at 245.6M. In comparison, MGRX has a market cap of 18.4M. Regarding current trading prices, SOPH is priced at $3.60, while MGRX trades at $1.73.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SOPH currently has a P/E ratio of -3.67, whereas MGRX's P/E ratio is -0.37. In terms of profitability, SOPH's ROE is -0.63%, compared to MGRX's ROE of -0.73%. Regarding short-term risk, SOPH is less volatile compared to MGRX. This indicates potentially lower risk in terms of short-term price fluctuations for SOPH.Check MGRX's competition here
SOPH vs ONMD Comparison July 2025
SOPH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SOPH stands at 245.6M. In comparison, ONMD has a market cap of 16M. Regarding current trading prices, SOPH is priced at $3.60, while ONMD trades at $0.51.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SOPH currently has a P/E ratio of -3.67, whereas ONMD's P/E ratio is -1.50. In terms of profitability, SOPH's ROE is -0.63%, compared to ONMD's ROE of +0.60%. Regarding short-term risk, SOPH is less volatile compared to ONMD. This indicates potentially lower risk in terms of short-term price fluctuations for SOPH.Check ONMD's competition here
SOPH vs BFRG Comparison July 2025
SOPH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SOPH stands at 245.6M. In comparison, BFRG has a market cap of 14.3M. Regarding current trading prices, SOPH is priced at $3.60, while BFRG trades at $1.52.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SOPH currently has a P/E ratio of -3.67, whereas BFRG's P/E ratio is -1.90. In terms of profitability, SOPH's ROE is -0.63%, compared to BFRG's ROE of -1.63%. Regarding short-term risk, SOPH is less volatile compared to BFRG. This indicates potentially lower risk in terms of short-term price fluctuations for SOPH.Check BFRG's competition here
SOPH vs BBLN Comparison July 2025
SOPH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SOPH stands at 245.6M. In comparison, BBLN has a market cap of 14.1M. Regarding current trading prices, SOPH is priced at $3.60, while BBLN trades at $0.55.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SOPH currently has a P/E ratio of -3.67, whereas BBLN's P/E ratio is -0.04. In terms of profitability, SOPH's ROE is -0.63%, compared to BBLN's ROE of +4.89%. Regarding short-term risk, SOPH is less volatile compared to BBLN. This indicates potentially lower risk in terms of short-term price fluctuations for SOPH.Check BBLN's competition here
SOPH vs INOV Comparison July 2025
SOPH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SOPH stands at 245.6M. In comparison, INOV has a market cap of 12.9M. Regarding current trading prices, SOPH is priced at $3.60, while INOV trades at $32.56.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SOPH currently has a P/E ratio of -3.67, whereas INOV's P/E ratio is 16.61. In terms of profitability, SOPH's ROE is -0.63%, compared to INOV's ROE of +0.03%. Regarding short-term risk, SOPH is more volatile compared to INOV. This indicates potentially higher risk in terms of short-term price fluctuations for SOPH.Check INOV's competition here
SOPH vs ETAO Comparison July 2025
SOPH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SOPH stands at 245.6M. In comparison, ETAO has a market cap of 9.8M. Regarding current trading prices, SOPH is priced at $3.60, while ETAO trades at $1.91.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SOPH currently has a P/E ratio of -3.67, whereas ETAO's P/E ratio is -0.01. In terms of profitability, SOPH's ROE is -0.63%, compared to ETAO's ROE of -13.69%. Regarding short-term risk, SOPH is less volatile compared to ETAO. This indicates potentially lower risk in terms of short-term price fluctuations for SOPH.Check ETAO's competition here
SOPH vs MSPR Comparison July 2025
SOPH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SOPH stands at 245.6M. In comparison, MSPR has a market cap of 9.1M. Regarding current trading prices, SOPH is priced at $3.60, while MSPR trades at $0.98.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SOPH currently has a P/E ratio of -3.67, whereas MSPR's P/E ratio is N/A. In terms of profitability, SOPH's ROE is -0.63%, compared to MSPR's ROE of -3.08%. Regarding short-term risk, SOPH is less volatile compared to MSPR. This indicates potentially lower risk in terms of short-term price fluctuations for SOPH.Check MSPR's competition here
SOPH vs HLTH Comparison July 2025
SOPH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SOPH stands at 245.6M. In comparison, HLTH has a market cap of 6.9M. Regarding current trading prices, SOPH is priced at $3.60, while HLTH trades at $0.04.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SOPH currently has a P/E ratio of -3.67, whereas HLTH's P/E ratio is -0.02. In terms of profitability, SOPH's ROE is -0.63%, compared to HLTH's ROE of -0.88%. Regarding short-term risk, SOPH is less volatile compared to HLTH. This indicates potentially lower risk in terms of short-term price fluctuations for SOPH.Check HLTH's competition here
SOPH vs ZCMD Comparison July 2025
SOPH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SOPH stands at 245.6M. In comparison, ZCMD has a market cap of 5.7M. Regarding current trading prices, SOPH is priced at $3.60, while ZCMD trades at $1.03.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SOPH currently has a P/E ratio of -3.67, whereas ZCMD's P/E ratio is -9.17. In terms of profitability, SOPH's ROE is -0.63%, compared to ZCMD's ROE of -0.03%. Regarding short-term risk, SOPH is less volatile compared to ZCMD. This indicates potentially lower risk in terms of short-term price fluctuations for SOPH.Check ZCMD's competition here
SOPH vs BFRGW Comparison July 2025
SOPH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SOPH stands at 245.6M. In comparison, BFRGW has a market cap of 5.4M. Regarding current trading prices, SOPH is priced at $3.60, while BFRGW trades at $1.52.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SOPH currently has a P/E ratio of -3.67, whereas BFRGW's P/E ratio is N/A. In terms of profitability, SOPH's ROE is -0.63%, compared to BFRGW's ROE of -1.63%. Regarding short-term risk, SOPH is less volatile compared to BFRGW. This indicates potentially lower risk in terms of short-term price fluctuations for SOPH.Check BFRGW's competition here
SOPH vs UPH Comparison July 2025
SOPH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SOPH stands at 245.6M. In comparison, UPH has a market cap of 5.3M. Regarding current trading prices, SOPH is priced at $3.60, while UPH trades at $0.30.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SOPH currently has a P/E ratio of -3.67, whereas UPH's P/E ratio is -0.07. In terms of profitability, SOPH's ROE is -0.63%, compared to UPH's ROE of -1.05%. Regarding short-term risk, SOPH is less volatile compared to UPH. This indicates potentially lower risk in terms of short-term price fluctuations for SOPH.Check UPH's competition here
SOPH vs ACON Comparison July 2025
SOPH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SOPH stands at 245.6M. In comparison, ACON has a market cap of 4.3M. Regarding current trading prices, SOPH is priced at $3.60, while ACON trades at $7.47.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SOPH currently has a P/E ratio of -3.67, whereas ACON's P/E ratio is -0.65. In terms of profitability, SOPH's ROE is -0.63%, compared to ACON's ROE of -1.27%. Regarding short-term risk, SOPH is more volatile compared to ACON. This indicates potentially higher risk in terms of short-term price fluctuations for SOPH.Check ACON's competition here
SOPH vs OTRK Comparison July 2025
SOPH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SOPH stands at 245.6M. In comparison, OTRK has a market cap of 4.1M. Regarding current trading prices, SOPH is priced at $3.60, while OTRK trades at $0.58.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SOPH currently has a P/E ratio of -3.67, whereas OTRK's P/E ratio is -0.03. In terms of profitability, SOPH's ROE is -0.63%, compared to OTRK's ROE of -2.70%. Regarding short-term risk, SOPH is less volatile compared to OTRK. This indicates potentially lower risk in terms of short-term price fluctuations for SOPH.Check OTRK's competition here
SOPH vs PEAR Comparison July 2025
SOPH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SOPH stands at 245.6M. In comparison, PEAR has a market cap of 4.1M. Regarding current trading prices, SOPH is priced at $3.60, while PEAR trades at $0.03.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SOPH currently has a P/E ratio of -3.67, whereas PEAR's P/E ratio is -0.08. In terms of profitability, SOPH's ROE is -0.63%, compared to PEAR's ROE of -0.39%. Regarding short-term risk, SOPH is less volatile compared to PEAR. This indicates potentially lower risk in terms of short-term price fluctuations for SOPH.Check PEAR's competition here
SOPH vs PEARW Comparison July 2025
SOPH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SOPH stands at 245.6M. In comparison, PEARW has a market cap of 4.1M. Regarding current trading prices, SOPH is priced at $3.60, while PEARW trades at $0.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SOPH currently has a P/E ratio of -3.67, whereas PEARW's P/E ratio is -0.00. In terms of profitability, SOPH's ROE is -0.63%, compared to PEARW's ROE of -0.39%. Regarding short-term risk, SOPH is less volatile compared to PEARW. This indicates potentially lower risk in terms of short-term price fluctuations for SOPH.Check PEARW's competition here
SOPH vs FOXO Comparison July 2025
SOPH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SOPH stands at 245.6M. In comparison, FOXO has a market cap of 3.8M. Regarding current trading prices, SOPH is priced at $3.60, while FOXO trades at $0.13.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SOPH currently has a P/E ratio of -3.67, whereas FOXO's P/E ratio is -0.02. In terms of profitability, SOPH's ROE is -0.63%, compared to FOXO's ROE of -0.01%. Regarding short-term risk, SOPH is less volatile compared to FOXO. This indicates potentially lower risk in terms of short-term price fluctuations for SOPH.Check FOXO's competition here
SOPH vs EUDAW Comparison July 2025
SOPH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SOPH stands at 245.6M. In comparison, EUDAW has a market cap of 3M. Regarding current trading prices, SOPH is priced at $3.60, while EUDAW trades at $0.10.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SOPH currently has a P/E ratio of -3.67, whereas EUDAW's P/E ratio is N/A. In terms of profitability, SOPH's ROE is -0.63%, compared to EUDAW's ROE of +3.05%. Regarding short-term risk, SOPH is less volatile compared to EUDAW. This indicates potentially lower risk in terms of short-term price fluctuations for SOPH.Check EUDAW's competition here
SOPH vs WGSWW Comparison July 2025
SOPH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SOPH stands at 245.6M. In comparison, WGSWW has a market cap of 1.8M. Regarding current trading prices, SOPH is priced at $3.60, while WGSWW trades at $0.06.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SOPH currently has a P/E ratio of -3.67, whereas WGSWW's P/E ratio is N/A. In terms of profitability, SOPH's ROE is -0.63%, compared to WGSWW's ROE of -0.17%. Regarding short-term risk, SOPH is less volatile compared to WGSWW. This indicates potentially lower risk in terms of short-term price fluctuations for SOPH.Check WGSWW's competition here
SOPH vs CMAX Comparison July 2025
SOPH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SOPH stands at 245.6M. In comparison, CMAX has a market cap of 1.6M. Regarding current trading prices, SOPH is priced at $3.60, while CMAX trades at $0.42.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SOPH currently has a P/E ratio of -3.67, whereas CMAX's P/E ratio is -0.00. In terms of profitability, SOPH's ROE is -0.63%, compared to CMAX's ROE of +30.94%. Regarding short-term risk, SOPH is less volatile compared to CMAX. This indicates potentially lower risk in terms of short-term price fluctuations for SOPH.Check CMAX's competition here
SOPH vs WORX Comparison July 2025
SOPH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SOPH stands at 245.6M. In comparison, WORX has a market cap of 1.6M. Regarding current trading prices, SOPH is priced at $3.60, while WORX trades at $0.43.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SOPH currently has a P/E ratio of -3.67, whereas WORX's P/E ratio is -0.48. In terms of profitability, SOPH's ROE is -0.63%, compared to WORX's ROE of -0.32%. Regarding short-term risk, SOPH is more volatile compared to WORX. This indicates potentially higher risk in terms of short-term price fluctuations for SOPH.Check WORX's competition here
SOPH vs LIFWZ Comparison July 2025
SOPH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SOPH stands at 245.6M. In comparison, LIFWZ has a market cap of 1.3M. Regarding current trading prices, SOPH is priced at $3.60, while LIFWZ trades at $0.07.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SOPH currently has a P/E ratio of -3.67, whereas LIFWZ's P/E ratio is N/A. In terms of profitability, SOPH's ROE is -0.63%, compared to LIFWZ's ROE of -3.08%. Regarding short-term risk, SOPH is more volatile compared to LIFWZ. This indicates potentially higher risk in terms of short-term price fluctuations for SOPH.Check LIFWZ's competition here
SOPH vs OTRKP Comparison July 2025
SOPH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SOPH stands at 245.6M. In comparison, OTRKP has a market cap of 1.1M. Regarding current trading prices, SOPH is priced at $3.60, while OTRKP trades at $0.23.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SOPH currently has a P/E ratio of -3.67, whereas OTRKP's P/E ratio is -0.08. In terms of profitability, SOPH's ROE is -0.63%, compared to OTRKP's ROE of -2.70%. Regarding short-term risk, SOPH is less volatile compared to OTRKP. This indicates potentially lower risk in terms of short-term price fluctuations for SOPH.Check OTRKP's competition here
SOPH vs KERNW Comparison July 2025
SOPH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SOPH stands at 245.6M. In comparison, KERNW has a market cap of 162.3K. Regarding current trading prices, SOPH is priced at $3.60, while KERNW trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SOPH currently has a P/E ratio of -3.67, whereas KERNW's P/E ratio is -0.00. In terms of profitability, SOPH's ROE is -0.63%, compared to KERNW's ROE of -2.22%. Regarding short-term risk, SOPH is less volatile compared to KERNW. This indicates potentially lower risk in terms of short-term price fluctuations for SOPH.Check KERNW's competition here
SOPH vs KERN Comparison July 2025
SOPH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SOPH stands at 245.6M. In comparison, KERN has a market cap of 162.3K. Regarding current trading prices, SOPH is priced at $3.60, while KERN trades at $0.31.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SOPH currently has a P/E ratio of -3.67, whereas KERN's P/E ratio is -0.01. In terms of profitability, SOPH's ROE is -0.63%, compared to KERN's ROE of -2.22%. Regarding short-term risk, SOPH is less volatile compared to KERN. This indicates potentially lower risk in terms of short-term price fluctuations for SOPH.Check KERN's competition here
SOPH vs ICCT Comparison July 2025
SOPH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SOPH stands at 245.6M. In comparison, ICCT has a market cap of 107.3K. Regarding current trading prices, SOPH is priced at $3.60, while ICCT trades at $0.02.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SOPH currently has a P/E ratio of -3.67, whereas ICCT's P/E ratio is N/A. In terms of profitability, SOPH's ROE is -0.63%, compared to ICCT's ROE of +20.01%. Regarding short-term risk, SOPH is more volatile compared to ICCT. This indicates potentially higher risk in terms of short-term price fluctuations for SOPH.Check ICCT's competition here
SOPH vs MSPRZ Comparison July 2025
SOPH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SOPH stands at 245.6M. In comparison, MSPRZ has a market cap of 66.7K. Regarding current trading prices, SOPH is priced at $3.60, while MSPRZ trades at $0.02.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SOPH currently has a P/E ratio of -3.67, whereas MSPRZ's P/E ratio is N/A. In terms of profitability, SOPH's ROE is -0.63%, compared to MSPRZ's ROE of -3.08%. Regarding short-term risk, SOPH is more volatile compared to MSPRZ. This indicates potentially higher risk in terms of short-term price fluctuations for SOPH.Check MSPRZ's competition here
SOPH vs LIFWW Comparison July 2025
SOPH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SOPH stands at 245.6M. In comparison, LIFWW has a market cap of 60.1K. Regarding current trading prices, SOPH is priced at $3.60, while LIFWW trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SOPH currently has a P/E ratio of -3.67, whereas LIFWW's P/E ratio is N/A. In terms of profitability, SOPH's ROE is -0.63%, compared to LIFWW's ROE of -3.08%. Regarding short-term risk, SOPH is more volatile compared to LIFWW. This indicates potentially higher risk in terms of short-term price fluctuations for SOPH.Check LIFWW's competition here
SOPH vs CMAXW Comparison July 2025
SOPH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SOPH stands at 245.6M. In comparison, CMAXW has a market cap of 36.4K. Regarding current trading prices, SOPH is priced at $3.60, while CMAXW trades at $0.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SOPH currently has a P/E ratio of -3.67, whereas CMAXW's P/E ratio is N/A. In terms of profitability, SOPH's ROE is -0.63%, compared to CMAXW's ROE of +30.94%. Regarding short-term risk, SOPH is more volatile compared to CMAXW. This indicates potentially higher risk in terms of short-term price fluctuations for SOPH.Check CMAXW's competition here
SOPH vs ACONW Comparison July 2025
SOPH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SOPH stands at 245.6M. In comparison, ACONW has a market cap of 14.6K. Regarding current trading prices, SOPH is priced at $3.60, while ACONW trades at $0.03.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SOPH currently has a P/E ratio of -3.67, whereas ACONW's P/E ratio is N/A. In terms of profitability, SOPH's ROE is -0.63%, compared to ACONW's ROE of -1.27%. Regarding short-term risk, SOPH is more volatile compared to ACONW. This indicates potentially higher risk in terms of short-term price fluctuations for SOPH.Check ACONW's competition here
SOPH vs MSPRW Comparison July 2025
SOPH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SOPH stands at 245.6M. In comparison, MSPRW has a market cap of 10K. Regarding current trading prices, SOPH is priced at $3.60, while MSPRW trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SOPH currently has a P/E ratio of -3.67, whereas MSPRW's P/E ratio is N/A. In terms of profitability, SOPH's ROE is -0.63%, compared to MSPRW's ROE of -3.08%. Regarding short-term risk, SOPH is less volatile compared to MSPRW. This indicates potentially lower risk in terms of short-term price fluctuations for SOPH.Check MSPRW's competition here
SOPH vs UTRS Comparison July 2025
SOPH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SOPH stands at 245.6M. In comparison, UTRS has a market cap of 888. Regarding current trading prices, SOPH is priced at $3.60, while UTRS trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SOPH currently has a P/E ratio of -3.67, whereas UTRS's P/E ratio is N/A. In terms of profitability, SOPH's ROE is -0.63%, compared to UTRS's ROE of -1.11%. Regarding short-term risk, SOPH is more volatile compared to UTRS. This indicates potentially higher risk in terms of short-term price fluctuations for SOPH.Check UTRS's competition here
SOPH vs CERN Comparison July 2025
SOPH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SOPH stands at 245.6M. In comparison, CERN has a market cap of 0. Regarding current trading prices, SOPH is priced at $3.60, while CERN trades at $94.92.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SOPH currently has a P/E ratio of -3.67, whereas CERN's P/E ratio is 55.84. In terms of profitability, SOPH's ROE is -0.63%, compared to CERN's ROE of +0.14%. Regarding short-term risk, SOPH is more volatile compared to CERN. This indicates potentially higher risk in terms of short-term price fluctuations for SOPH.Check CERN's competition here
SOPH vs SMFRW Comparison July 2025
SOPH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SOPH stands at 245.6M. In comparison, SMFRW has a market cap of 0. Regarding current trading prices, SOPH is priced at $3.60, while SMFRW trades at $0.02.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SOPH currently has a P/E ratio of -3.67, whereas SMFRW's P/E ratio is N/A. In terms of profitability, SOPH's ROE is -0.63%, compared to SMFRW's ROE of -0.17%. Regarding short-term risk, SOPH is less volatile compared to SMFRW. This indicates potentially lower risk in terms of short-term price fluctuations for SOPH.Check SMFRW's competition here
SOPH vs CHNG Comparison July 2025
SOPH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SOPH stands at 245.6M. In comparison, CHNG has a market cap of 0. Regarding current trading prices, SOPH is priced at $3.60, while CHNG trades at $27.49.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SOPH currently has a P/E ratio of -3.67, whereas CHNG's P/E ratio is -152.72. In terms of profitability, SOPH's ROE is -0.63%, compared to CHNG's ROE of -0.05%. Regarding short-term risk, SOPH is more volatile compared to CHNG. This indicates potentially higher risk in terms of short-term price fluctuations for SOPH.Check CHNG's competition here
SOPH vs MSPRV Comparison July 2025
SOPH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SOPH stands at 245.6M. In comparison, MSPRV has a market cap of 0. Regarding current trading prices, SOPH is priced at $3.60, while MSPRV trades at $0.07.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SOPH currently has a P/E ratio of -3.67, whereas MSPRV's P/E ratio is N/A. In terms of profitability, SOPH's ROE is -0.63%, compared to MSPRV's ROE of -3.08%. Regarding short-term risk, SOPH is less volatile compared to MSPRV. This indicates potentially lower risk in terms of short-term price fluctuations for SOPH.Check MSPRV's competition here